A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma

Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Xin Zhang(Chinese National Human Genome Center), Xiaohong Han(Chinese Academy of Medical Sciences & Peking Union Medical College), Chuan Jin(Guangzhou Medical University), Weijun Fu(Shanghai Changzheng Hospital), Haiyan Yang(Chinese Academy of Sciences), Ying Cheng(Jilin Province Tumor Hospital), Jianmin Yang(Canadian Food Inspection Agency), Eugene Liu, Dong Wang(Army Medical University), Tao Sun, Chaoming Ma, Jianda Hu(Fujian Medical University), Hang Su(307th Hospital of Chinese People’s Liberation Army), Jiancheng Cheng, Xin Du(Guangdong Provincial People's Hospital), Yongping Song(First Affiliated Hospital of Zhengzhou University), Wei Li(Changchun Observatory), Xiaohong Zhang(Peking University), Mingzhi Zhang(First Affiliated Hospital of Zhengzhou University), Li Liu(Air Force Medical University), Zhao Wang(Capital Medical University), Xiuli Wang(Third Hospital of Hebei Medical University), Yu Yang(Fujian Provincial Cancer Hospital), Jifeng Feng(Nanjing Medical University), Qingyuan Zhang(Third Affiliated Hospital of Harbin Medical University), Huaqing Wang(Beijing University of Chemical Technology), Xiaoyan Ke(Peking University), Yu Ding(Hubei Cancer Hospital), Pingyong Yi(Hunan Cancer Hospital), Guoan Chen(Southern University of Science and Technology), Xielan Zhao(Central South University), Yun Chen(Zhejiang Chinese Medical University), Alvin Luk, Xiaonan Hong(Lymphoma Research Foundation), Zhengming Jin(Soochow University), Katherine Chai, Jie Jin(Blood Center of Zhejiang Province), Yang Zhang(Dalian Medical University), Huilai Zhang(Tianjin Medical University Cancer Institute and Hospital)
Journal of Hematology & Oncology
April 16, 2020
10.1186/s13045-020-00871-9
Cited by 50

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k